ARTICLE | Management Tracks
Hayes joins Fulcrum as chief commercial officer
Plus: ImmunityBio, Finch, Rhythm, Infinity, Locanabio and more
September 9, 2021 1:28 AM UTC
Genetic rare disease company Fulcrum Therapeutics Inc. (NASDAQ:FULC) hired Mel Hayes as chief commercial officer. Hayes was global head of commercial, VP of rare blood disorders at the Genzyme unit of Sanofi (Euronext:SAN; NASDAQ:SNY), before which he held roles at Shire plc, Baxter International Inc. (NYSE:BAX), Bayer AG (Xetra:BAYN) and Bristol Myers Squibb Co. (NYSE:BMY).
ImmunityBio Inc. (NASDAQ:IBRX) hired Helen Luu as chief commercial officer, and Sigrid Schreiner as SVP of global market access. Luu was CEO at CAR-T developer Cell BT Inc., and Schreiner was SVP of global market access and distribution at Stemline Therapeutics Inc., which is now Menarini Group...